Drugs / IL-21
IL-21
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00336986 | Sep 2004 → Oct 2007 | cancer, melanoma | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-21 | “Interleukin-21 (IL-21) is a common γ-chain cytokine produced by T helper and natural killer T (NKT) cells.” PMID 25505948 ↗ Oct 2013 |
| Known as | Interleukin-21 | “Interleukin-21 (IL-21) is a common γ-chain cytokine produced by T helper and natural killer T (NKT) cells.” PMID 25505948 ↗ Oct 2013 |
| Known as | recombinant IL-21 | “recombinant IL-21 (rIL-21) was fast-tracked into early-phase clinical trials of patients with various malignancies.” PMID 25505948 ↗ Oct 2013 |
| Known as | rIL-21 | “recombinant IL-21 (rIL-21) was fast-tracked into early-phase clinical trials of patients with various malignancies.” PMID 25505948 ↗ Oct 2013 |
| Modality | Protein / enzyme biologic | “Interleukin-21 (IL-21) is a common γ-chain cytokine produced by T helper and natural killer T (NKT) cells.” PMID 25505948 ↗ Oct 2013 |
| Route | Intravenous | “IL-21 will be administered intravenously.” NCT00336986 ↗ |